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infection by downregutating celt surface CCR5 ex- 
pression and enhanced HIV-1 expression by transac- 
tivating HIV-1 LTR promoter. ProstagLandin E2, one 
of the major constituents of seminal fluid, exerted 
similar effects on HIV-1 infection of MDM. Semi- 
hal fluid enhanced efficiency of HIV-1 transmission 
from MDDC to [ymphocytes, and such effect was 
diminished by anti-DC-SIGN antibody but not CCR5 
inhibitors. 
Conclusions: Differential effects of seminal fluid on 
[ymphocytes and MDM may favor accumulation of 
macrophage-derived RS-HIV-1 in semen; however, 
seminal fluid appears to help dendritic ceLLs in 
recessive genitaL/rectaL mucosa transmit HIV-1 to 
[ymphocytes, irreLevantLy to whether it is RS- or 
X4-HIV-1. 
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Background: To evaluate the impact of discontinu- 
ing Enfuvirtide (T-20) in heavily pretreated HIV-1- 
infected patients. 
Methods: Pts treated with T-20 between 4/2001- 
12/2004 within the Swiss HIV Cohort Study (SHCS). 
FoLLow-up until 2/2006. MuLtivariate analysis (Cox 
hazards modeL) in a subgroup of pts with baseline 
CD4 <200 ceLLs/pL who had been treated with T-20 
for >12 weeks. 
Results: 105 pts were analyzed. Most pts were 
male (89%), median age 44 (27-66), prior AIDS 67%, 
HCV 26%, intravenous drug use (IDU) 23%. Me- 
dian baseline VL was 4.9 Log~0 copies/mL and CD4 
84 cetts/mL. During foLLow-up 41/105 (39%) pts dis- 
continued T-20, due to the patient's wish (39%), vi- 
roLogicaL failure (19%), ART-toxicity (12%). Pts stop- 
ping T-20 had a more advanced isease at baseline 
compared to those who continued treatment (prior 
AIDS 77% versus 61%, CD4 49 versus 107). In the 
on-treatment analysis VL<400c/mL was achieved 
by 57/97 (59%), 48/77 (62%), 19/30 (63%) and 
9/14 (64%) pts after 24, 48, 96 and 144 weeks, 
respectively. In the intention-to-treat nalysis 56%, 
54%, 38% and 33% pts achieved VL<400 c/mL after 
24, 48, 96 and 144 weeks, respectively. After stop- 
ping T-20, 20% of 41 pts maintained VL<400c/mL 
after 12, 24 and 48 weeks. On treatment, a median 
CD4 increase of 63, 93, 147 and 108cetts/pL above 
baseline was observed at week 24, 48, 96 and 
144, respectively. After discontinuing T-20, CD4 
declined from 72 by 5, 16 and 15cetts/mL after 
12, 24 and 48 weeks, respectively. In a multivariate 
analysis of 74 pts with baseline CD4 <200 treated 
>12 weeks, higher CD4 at baseline was the only 
predictor of CD4 response *200 to T-20 (adjusted 
HR 4.26, 95%CI 2.25-8.08, p < 0.001). New AIDS- 
defining events occurred in 7/105 pts during treat- 
ment and in 10/41 pts after stopping T-20.6 pts 
died during treatment (4 HIV-retated); 17 after 
stopping T-20 (11 HIV-retated). 
Conclusions: Our data indicate that T-20 should 
not be initiated too Late. In most pts stopping T-20 
viremia is not controLLed and CD4 tend to decrease. 
Discontinuation of T-20 may be associated with a 
poorer prognosis. 
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Background: IsoLated toxopLasmic retinochoroidi- 
tis rarely occurs as first and soLeLy opportunistic 
infection in HIV positive patients. The benefit of 
treatment other than HAART is debated and there 
is no consensus for the best regimen. However, 
HAART can Lead to immune recovery vitritis, caus- 
ing therapeutic chaLLenges. 
Objective: We present a 34 year old HIV posi- 
tive man with a toxopLasmic retinochoroiditis and 
immune recovery vitritis after initiating HAART. 
Successful treatment included parabuLbar steroid 
injection. 
Methods: CD4 count and viral Load were examined 
in intervals of 3 months. Serial ophthaLmoLogic 
